Seattle, United States
Cyrus Biotechnology, founded in 2014, is a pre-clinical biotech company focused on creating novel biologics using computational structure biology, AI, and protein engineering. Their unique approach addresses serious unmet medical needs through innovative programs across multiple indications.
The company leverages core software from the renowned David Baker lab at the University of Washington and has established partnerships with over 90 industry leaders. With headquarters in the United States, Cyrus Biotechnology collaborates with leading biotech and pharma companies to transition discoveries into clinical applications.
Supported by well-established investors such as Orbimed, Trinity Ventures, and Agent Capital, Cyrus Biotechnology secured an $18.00M Series B investment in December 2021. The company’s growth is further augmented by support from US and Asian biotech and tech investors, underscoring its robust financial backing in the biotechnology, nutrition, and pharmaceutical industries.
